Search Result

Pathways Recommended:	PROTAC

Results for "

PROTAC CDK9 degrader

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (30) Ligands for Target Protein for PROTAC (7) AAK1 (1) Apoptosis (4) c-Myc (1) Caspase (1) DNA/RNA Synthesis (1) E3 Ligase Ligand-Linker Conjugates (2) Ephrin Receptor (1) FGFR (1) FLT3 (1) HIV (2) IRAK (1) Itk (1) Ligands for E3 Ligase (1) MAP4K (1) MELK (1) p38 MAPK (1) PARP (1) PROTACs (23) Reference Standards (1) Target Protein Ligand-Linker Conjugates (2) ULK (1) Wee1 (1)
By Research Areas:	Cancer (33) Infection (2) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (1)

Targets Recommended: CDK PROTAC-Linker Conjugates for PAC PROTAC Linkers Ligands for Target Protein for PROTAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-123937

THAL-SNS-032 Maximum Cited Publications 10 Publications Verification	PROTACs CDK	Cancer
THAL-SNS-032 is a selective *CDK9* degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN) .

HY-103628

PROTAC CDK9 Degrader-1 2 Publications Verification	PROTACs CDK	Cancer
PROTAC CDK9 Degrader-1 is a PROTAC connected by ligands for Cereblon and CDK as a selective *CDK9* degrader.

HY-130665

TL12-186 1 Publications Verification	PROTACs CDK	Cancer
TL12-186 is a Cereblon-dependent multi-kinase *PROTAC* degrader. Multi-kinases include CDK, BTK, FLT3, Aurora kinases, TEC, ULK, ITK, et al. TL12-186 inhibits CDK2/cyclin A (IC₅₀=73 nM) and CDK9/cyclin T1 (IC₅₀=55 nM) .

HY-130709

PROTAC CDK2/9 Degrader-1	PROTACs CDK	Cancer
PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for CDK2 (DC₅₀=62 nM) and *CDK9* (DC₅₀=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC₅₀=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with Cereblon ligand .

HY-173523

KI-CDK9d-32	PROTACs CDK c-Myc	Cancer
KI-CDK9d-32 is a highly selective and potent *CDK9* PROTAC degrader (DC₅₀: 0.89 nM). KI-CDK9d-32 promotes the ubiquitination and degradation of CDK9. KI-CDK9d-32 inhibits the MYC pathway and disrupts nucleolar homeostasis. KI-CDK9d-32 exhibits anticancer activity against acute lymphoblastic leukemia and pancreatic cancer. (Pink: CDK9 ligand (HY-153718); Blue: E3 ligase CRBN ligand (HY-163233); Black: Linker (HY-W011657); E3 ligase CRBN ligand-linker conjugate (HY-173525)) .

HY-112811

PROTAC CDK9 degrader-2	PROTACs CDK	Cancer
PROTAC CDK9 degrader-2 (compound 11c) is a potent and selective *CDK9* degrader based on *PROTAC, with an IC₅₀* of 17 μM in MCF-7 cell lines. Natural product Wogonin (CDK ligand) binds ubiquitin E3 ligase Cereblon (CRBN) via a linker to form PROTAC .

HY-148065

FMF-06-098-1	PROTACs Wee1 CDK AAK1 ULK MELK Itk IRAK Ephrin Receptor FGFR MAP4K p38 MAPK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
FMF-06-098-1 is a multi-target kinase *PROTAC* degrader. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .

HY-168518

PROTAC CDK9 degrader-9	PROTACs CDK	Cancer
PROTAC CDK9 degrader-9 (compound 29) is a highly selective and efficient *CDK9* degrader based on PROTAC technology. PROTAC CDK9 degrader-9 can be used in anti-cancer research .

HY-162706

BSJ-5-63 1 Publications Verification	PROTACs CDK	Cancer
BSJ-5-63 is a potent CDK12, CDK7, *CDK9* PROTAC degrader. BSJ-5-63 BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K. BSJ-5-63 decreases the mRNA expression of BRCA1, BRCA2. BSJ-5-63 shows anticancer activity and has the potential for the research of prostate cancer (Pink: ligand for target protein (HY-150948); black: linker (HY-W140827); Blue: E3 ligase ligand (HY-112078)) .

HY-149964

PROTAC CDK9 degrader-7	PROTACs CDK	Cancer
PROTAC CDK9 degrader-7 is a *PROTAC* targeting to *CDK9* sepcifically. PROTAC CDK9 degrader-7 mediates CDK9 degradation via the proteasome .

HY-178861

dCDK9-202	PROTACs CDK Caspase PARP Apoptosis	Cancer
dCDK9-202 a potent **CDK9 PROTAC** degrader with an DC₅₀ value of 3.5 nM. dCDK9-202 exhibits broad-spectrum anti-tumor activity and extensively disrupts the oncogenic transcriptome. dCDK9-202 can activate Caspase-3/7, increase the level of cleaved PARP, and directly induce apoptosis of tumor cells. dCDK9-202 effectively inhibits TC-71 tumor growth without any signs of toxicity in mice. dCDK9-202 can be used for the study of EGFR-driven cancers such as sarcoma (Pink: CDK9 ligand (HY-178862); Blue: CRBN ligand (HY-W248665); Black: Linker (HY-N8015)) .

HY-115728

PROTAC CDK9 degrader-4	PROTACs	Cancer
PROTAC CDK9 degrader-4 is a highly potent and efficacious *CDK9* degrader for targeting transcription regulation.

HY-170978

PROTAC CDK9 degrader-11	PROTACs CDK	Cancer
PROTAC CDK9 degrader-11 (Compound C3) is an orally active PROTAC degrader for *CDK9* with DC₅₀ of 1.09 nM. PROTAC CDK9 degrader-11 exhibits cytotoxicity in multi small cell lung cancer cell with IC₅₀ of nanomolar levels. PROTAC CDK9 degrader-11 arrests cell cycle at G0/G1 phase, inhibits the cell invasion in DMS114 and DMS53 cell. PROTAC CDK9 degrader-11 exhibits antitumor efficacy in NCI-H446 xenograft mouse models .(Pink: ligand for target protein CDK9 ligand 3 (HY-170979); Black: linker; Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 56 (HY-W247437))

HY-155218

TMX-2172	PROTACs CDK	Cancer
TMX-2172 is a selective bivalent cereblon-recruiting *PROTAC*-based dual CDK2 and CDK5 degrader with IC₅₀ values of 6.5 nM and 6.8 nM, respectively. TMX-2172 shows selectivity for CDK2 and CDK5 over other cell cycle CDKs (CDK1, CDK4, and CDK6) and transcriptional CDKs (CDK7 and CDK9). TMX-2172 inhibits CDK2/CDK5 enzymatic activity, induces their proteasomal degradation, reduces ASCL1 protein levels and half-life, induces cancer cell death, and exerts antiproliferative effects. TMX-2172 can be used for the research of ovarian cancer and small cell lung cancer .

HY-149962

PROTAC CDK9 degrader-5	PROTACs CDK	Cancer
PROTAC CDK9 degrader-5 is a *PROTAC* targeting to *CDK9* sepcifically. PROTAC CDK9 degrader-5 mediates CDK9 degradation via the proteasome. PROTAC CDK9 degrader-5 degrades CDK9 with DC₅₀s of 0.10 μM and 0.14 μM for the CDK9₄₂ and CDK9₅₅ isoforms, respectively .

HY-148521

PROTAC FLT3/CDK9 degrader-1	CDK FLT3 PROTACs Apoptosis	Cancer
PROTAC FLT3/CDK9 degrader-1 is a potent FLT3 and *CDK9* dual PROTAC degrader. PROTAC FLT3/CDK9 degrader-1 induces apoptosis and effective degradation of target proteins FLT3 and CDK9. PROTAC FLT3/CDK9 degrader-1 has the potential for the research of FLT3-ITD mutated AML .

HY-149963

PROTAC CDK9 degrader-6	PROTACs CDK	Cancer
PROTAC CDK9 degrader-6 is a *PROTAC* targeting to *CDK9* sepcifically. PROTAC CDK9 degrader-6 mediates CDK9 degradation via the proteasome. PROTAC CDK9 degrader-6 degrades CDK9 with DC₅₀s of 0.10 μM and 0.14 μM for the CDK9₄₂ and CDK9₅₅ isoforms, respectively .

HY-149870

PROTAC CDK9 degrader-8	PROTACs CDK	Cancer
PROTAC CDK9 degrader-8 (compound 21) is a potent **PROTAC CDK9** degrader with an IC₅₀ value of 0.01 μM. PROTAC CDK9 degrader-8 can be used in research of cancer .

HY-156795

PROTAC CDK9/CycT1 Degrader-2	CDK	Cancer
PROTAC CDK9/CycT1 Degrader-2 is a inhibitor of *CDK9, with the IC₅₀* of 45 nM .

HY-181231

PROTAC CDK9 degrader-12	PROTACs CDK HIV DNA/RNA Synthesis	Infection
PROTAC CDK9 degrader-12 is a selective **CDK9 PROTAC** degrader with a DC₅₀ of 23 nM. PROTAC CDK9 degrader-12 induces proteasome-dependent degradation of CDK9, blocks CDK9-mediated HIV-1 transcriptional elongation, and reduces HIV-1 RNA synthesis. PROTAC CDK9 degrader-12 is applicable to research related to HIV-1 infection .

HY-103628R

PROTAC CDK9 Degrader-1 (Standard)	Reference Standards PROTACs CDK	Cancer
PROTAC CDK9 Degrader-1 (Standard) is the analytical standard of PROTAC CDK9 Degrader-1 (HY-103628). This product is intended for research and analytical applications. PROTAC CDK9 Degrader-1 is a PROTAC connected by ligands for Cereblon and CDK as a selective CDK9 degrader.

HY-W247437

E3 ligase Ligand 56	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 56 is the ligand for E3 ligase Cereblon and can be used for syntheisis of PROTAC CDK9 degrader-11 (HY-170978) .

HY-164906

TMX-2138	CDK PROTACs	Cancer
TMX-2138 is a CDKs PROTAC degrader, with IC₅₀s of 8.7 nM, 10.9 nM, 7.0 nM and 25.7 nM for CDK1/cyclinB, CDK2/cyclinA, CDK5/p25 and CDK9/cyclinT1, respectively. TMX-2138 promotes ubiquitination and degradation of CDKs. TMX-2138 can be used for the research of ovarian cancer (Pink: CDKs ligand (HY-151071); Blue: E3 ligase CRBN ligand (HY-14658); Black: linker (HY-W008352)) .

HY-178452

PROTAC CDK4/6/9 degrader 1	PROTACs CDK Apoptosis	Cancer
PROTAC CDK4/6/9 degrader 1 is a CDK4/6/9 PROTAC degrader. PROTAC CDK4/6/9 degrader 1 degrades CDK4, CDK6, and *CDK9* in TNBC cells and inhibits TNBC cell proliferation. PROTAC CDK4/6/9 degrader 1 induces G1 phase arrest, promotes apoptosis, and suppresses cell migration and invasion in TNBC cells. PROTAC CDK4/6/9 degrader 1 can be used for the study of triple-negative breast cancer (TNBC). (Pink: CDK4/6/9 ligand (HY-168440), Blue: CRBN Ligand (HY-14658), Black: Linker (HY-178512), E3 ligase ligand-linker conjugate (HY-178515)) .

HY-178862

CDK9 ligand-Linker Conjugate	Target Protein Ligand-Linker Conjugates	Cancer
CDK9 ligand-Linker Conjugate is a synthesized CDK9 ligand-linker conjugate that can be used for synthesis of dCDK9-202 (HY-178861). dCDK9-202 is a potent **CDK9 PROTAC** degrader with anti-tumor activity .

HY-130852

CDK9-IN-11	Ligands for Target Protein for PROTAC CDK	Cancer
CDK9-IN-11 is a potent *CDK9* inhibitor. CDK9-IN-11 is the ligand for the PROTAC CDK9 Degrader-1 (HY-103628) .

HY-130850

CDK9-IN-10	CDK Ligands for Target Protein for PROTAC	Cancer
CDK9-IN-10 is a potent *CDK9* inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811) .

HY-170979

CDK9 ligand 3	Ligands for Target Protein for PROTAC CDK	Cancer
CDK9 ligand 3 is the ligand for *CDK9* and can be used for synthesis of PROTAC degrader PROTAC CDK9 degrader-11 (HY-170978) .

HY-156083

CDK9-IN-28	CDK	Cancer
PROTAC CDK9/CycT1 Degrader-1 (compounds 10) is a potent inhibitor of *CDK9. PROTAC* CDK9/CycT1 Degrader-1 can be used as a *PROTAC* target protein ligand for *PROTAC* synthesis. PROTAC CDK9/CycT1 Degrader-1 shows strong anti-proliferative activity in solid tumors .

HY-115729A

(R)-PROTAC CDK9 ligand-1	Ligands for Target Protein for PROTAC CDK	Cancer
(R)-PROTAC CDK9 ligand-1 (Compound 19.4) is a *CDK9*-targeting degrader that can be used to synthesize PROTAC with antitumor activity .

HY-168897

LC3B ligand 1	Ligands for Target Protein for PROTAC	Others
LC3B ligand 1 is a ligand for the target protein of PROTAC and can be used for the synthesis of PROTAC CDK9 autophagic degrader 1 (HY-168896) .

HY-168898

1,3-Propanediol-SNS-032	Target Protein Ligand-Linker Conjugates	Others
1,3-Propanediol-SNS-032 is a target protein ligand and linker conjugate, which can be used for the synthesis of PROTAC CDK9 autophagic degrader 1 (HY-168896) .

HY-182812

Thalidomide-5-F-6-piperidinylpiperazin	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-5-F-6-piperidinylpiperazin is an ligands for E3 ligase-linker conjugate, which is used for the synthesis of *PROTAC* CDK9 degrader-9 (HY-168518) .

HY-182810

CDK9 ligand 5	Ligands for Target Protein for PROTAC CDK	Cancer
CDK9 ligand 5 (Compound 48) is a *CDK9* ligand. CDK9 ligand 5 can be used as a ligand for target protein for PROTAC to develop and design degraders of PROTAC CDK9, such as PROTAC CDK9 degrader-9 (HY-168518). CDK9 ligand 5 can be used in cancer research .

HY-181275

CDK9 ligand 4	Ligands for Target Protein for PROTAC CDK HIV	Infection
CDK9 ligand 4 is a *CDK9* ligand. As a ligand for target protein for PROTAC (Ligands for Target Protein for PROTAC), CDK9 ligand 4 serves for the development and design of PROTAC CDK9 degraders, such as PROTAC CDK9 degrader-12 (HY-181231). CDK9 ligand 4 is applicable to the research of HIV-1 infection .

HY-170980

E3 Ligase Ligand-linker Conjugate 166	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 Ligase Ligand-linker Conjugate 166 is the conjugate composed of a E3 ligase ligand and a linker. E3 Ligase Ligand-linker Conjugate 166 can be used for synthesis of PROTAC CDK9 degrader-11 (HY-170978) .

HY-181490

WWZ-11-098	PROTACs CDK Apoptosis	Cancer
WWZ-11-098 is a selective CDK6 PROTAC degrader with DC₅₀ of 2.6 nM. WWZ-11-098 induces degradation of CDK6 in a CRBN-dependent manner, while sparing CDK1, CDK2, CDK4, and CDK9. WWZ-11-098 induces apoptosis, G1-S cell cycle arrest and shows anti-proliferative activity in cancer cells. WWZ-11-098 exhibits antitumor efficacy in a xenograft model without signs of toxicity. WWZ-11-098 can be used for the research of leukemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PROTAC CDK9 degrader

Inhibitors & Agonists